Trial Profile
A Partially Blinded Randomized Clinical Trial to Study the Immunogenicity and Safety of Intradermal Administration of ZOSTAVAX (V211).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Varicella zoster virus vaccine live (Primary) ; Varicella zoster virus vaccine live (Primary)
- Indications Herpes zoster
- Focus Adverse reactions; Pharmacodynamics
- Acronyms V211-051 AM2
- Sponsors Merck Sharp & Dohme
- 20 Feb 2013 Planned end date changed from 1 Sep 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 27 Nov 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 27 Nov 2012 Planned End Date changed from 1 May 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.